Abstracts tagged "juvenile dermatomyositis and outcomes"

Abstract Number: 1014 • 2016 ACR/ARHP Annual Meeting
Juvenile Dermatomyositis: What Comes Next?
Christina A. Boros¹, Liza J. McCann², Nicola Ambrose³, Mario Cortina-Borja⁴, Stephanie Simou⁵, Clarissa Pilkington⁶ and Lucy R Wedderburn⁷, ¹UCL INstiute of Chuld Health, London, United Kingdom, ²Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ³Department of Vascular Sciences, National Heart and Lung Institute, Imperial College, London, United Kingdom, ⁴Population, PLociy and Practice, UCL Institute of Child Health, London, United Kingdom, ⁵Infection, Inflammation and Rheumatology, UCL Institute of Child Health, London, United Kingdom, ⁶Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, United Kingdom, ⁷Paediatric Rheumatology Department, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom
Background/Purpose: Few studies describe the natural course and long term outcomes of myositis in childhood in large, prospectively-followed patient cohorts, treated in the modern era.…
Abstract Number: 1375 • 2016 ACR/ARHP Annual Meeting
A Five Year Study of 102 Children with Juvenile Myositis: Disease Course and Outcomes
Lauren M. Pachman^1,2,3, Megan L. Curran⁴, Gabrielle A. Morgan^5,6, Maria C. Amoruso^1,7, Ira N. Targoff^8,9 and Chiang-Ching Huang¹⁰, ¹Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ²Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Rheumatology/Immunology, Ann & Robert H. Lurie Children's Hosptial of Chicago, Chicago, IL, ⁴Division of Rheumatology, Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago/Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Cure JM Program of Excellence in Myositis Research, Chicago, IL, ⁶Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁷Immunology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁸Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹University of Oklahoma, Oklahoma City, OK, ¹⁰Zilber School of Public Health, University of Wisconsin, Milwaukee, Milwaukee, WI
Background/Purpose: Children with juvenile myositis (JM) have a variable disease course, in part associated with myositis specific/associated antibodies (MSA). Time to off medications has not…
Abstract Number: 3177 • 2015 ACR/ARHP Annual Meeting
Whole-Body MRI: A Valuable Diagnostic Tool for the Assessment of Disease Damage in Juvenile Dermatomyositis
Clara Malattia¹, Agnese Beltramo¹, Isabella Buffoni¹, Annalisa Madeo¹, Francesca Magnaguagno², Stefania Viola¹ and Alberto Martini^1,3, ¹Istituto G Gaslini, Pediatria II, Reumatologia, Genova, Italy, ²Istituto G Gaslini, UO Radiologia Pediatrica, Genoa, Italy, ³Pediatria, Istituto G Gaslini, Pediatria II, Reumatologia, Genova, Italy
Background/Purpose: Although the prognosis of JDM has significantly improved during the past decade, some patients still experience persistent active disease, which potentially leads to irreversible…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].